Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Strengthens With Longer Treatment in EGFR L858R Lung Cancer

Lantern Pharma announced updated HARMONIC Phase 2 trial data showing that the progression-free survival (PFS) benefit from LP-300 improves with longer treatment duration in patients with EGFR exon 21 L858R-mutant non-small cell lung cancer (NSCLC). Patients completing more cycles of therapy demonstrated higher median PFS outcomes, with emerging signals suggesting deeper and more durable responses in this genetically defined subgroup. The findings further support the FDA-aligned strategy to enrich enrollment for L858R patients and extend treatment cycles, aiming to optimize outcomes in a population with limited post-TKI therapeutic options.